Abstract
Advances in the treatment of childhood acute lymphoblastic leukemia (ALL) have been striking while results have been less impressive in adults who develop this disease. Obvious differences in a patient’s ability to withstand cytotoxic therapy may account, in part, for these findings, but the biologic behaviour of the disease in the two age groups appears to be different; relapses are more frequent and cures less common in adults. In fact, age alone appears to be the most important prognostic factor in ALL. The demonstration of the efficacy of bone marrow transplantation in advanced disease as well as the marked improvements in supportive care and the development of effective high-dose cytotoxic preparative regimens, especially those which use total body irradiation, however, have paved the way for transplantation in first complete remission. Formerly, most adult ALL patients who underwent bone marrow transplant did so in relapse, or in second or subsequent remission. In most studies 40–50 % of first remission adult patients attain long-term disease-free survival after allogeneic and autologous bone marrow transplant. Relapses are considerably higher in the autologous transplant group when compared to the allogeneic group, but the latter population may experience increased morbidity and mortality due to graft-versus-host disease and opportunistic infection. These differences may reflect the beneficial graft-versus-leukemia effect in the allograft as well as infusion of autoiogous leukemia cells in the autograft but neither transplant subtype appears superior. Compared to more conventional approaches, however, transplantation may offer improved disease-free survival, although patient selection appears to significantly influence outcome. These many inherent biases must be noted when comparing markedly different approaches,e.g. transplantversus conventional therapy. The challenge of demonstrating which therapy is superior for adult ALL patients can only be addressed in a well-designed, prospective, randomized trial.
Similar content being viewed by others
References
Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia. 30 years’ experience at St. Jude Children’s Research Hospital.N Engl J Med.,329, 1289 (1993).
Hoelzer D. Acute lymphoblastic leukemia-progress in children, less in adults.N Engl J Med.,329, 1343 (1993).
Hoelzer D, Thiel E, Löftier H, Büchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Rühl H, Maschmeyer G, Lipp T, Nowrousian MR, Burkert M, Gerecke D, Pralle H, Müller U, Lunscken C, Fülle H, Ho AD, Küchler R, Busch FW, Schneider W, Görg C, Emmerich B, Braumann D, Vaupel HA, von Paleske A, Barrels H, Neiss A, Messerer D. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.Blood,71, 123 (1988).
Gaynor J, Chapman D, Little D, McKenzie S, Miller W, Andreeff M, Arlin Z, Berman E, Kempin S, Gee T, Clarkson B. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia. The Memorial Hospital experience since 1969.J Clin Oncol.,6, 1014 (1988).
Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, Morrison F, Saiki JH, Metz E, Rivkin SE, Grever MR, Boldt D, and the Southwest Oncology Group. Treatment of acute lymphoblastic leukemia in adults with intensive induction consolidation and maintenance chemotherapy.Blood,73, 57 (1989).
Blacklock HA, Matthews JR, Buchanan JG, Ockelford PA, Hill RS. Improved survival from acute lymphoblastic leukemia in adolescents and adults.Cancer,48, 1931 (1981).
Schauer P, Arlin ZA, Mertelsmann R, CL,’rincione C, Friedman A, Gee TS, Dowling M, Kempin S, Straus DJ, Koziner B, McKenzie S, Thaler HT, Dufour P, Little C, Dellaquilla C, Ellis S, Clarkson B. Treatment of acute lymphoblastic leukemia in adults, results of the L-10 and L-10M protocols.J Clin Oncol.,1, 462 (1983).
Sanchez-Fayos J, Outeirino J, Villalobos E, Paniagua C, Calabuig T, Lite M, Figuera A, Perez-Rus G, Prieto E, Serrano J, Escudero A. Acute lymphoblastic leukemia in adults, results of a ‘total-therapy’ programme in 47 patients over 15 years old.Br J Haematol.,59, 689 (1985).
Editorial. Acute lymphoblastic leukemia in adults.Lancet, 1, 952 (1986).
Marcus RE, Catovsky D, Johnson SA, Gregory WM, Talavera JG, Goldman JM, Galton DAG. Adult acute lymphoblastic leukemia, a study of prognostic features and response to treatment over a ten year period.Br J Haematol.,53, 175 (1986).
Hoelzer D, Gale RP. Acute lymphoblastic leukemia in adults, recent progress, future directions.Semin Hematol.,24, 27 (1987).
Ringdén O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA, Speck B, Veum-Stone JA, de Witte T, Bortin MM. Outcome after allogeneic bone marrow transplant for leukemia in older adults.J Am Med Assoc.,270, 57 (1993).
Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults. age, distribution, BCR breakpoint and prognostic significance.Leukemia,5, 196 (1991).
Maurer J, Janssen JWG, Thiel E, van Denderen J, Ludwig W-D, Aydemir O, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Holzer D, Bartram CR. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the potymerase chain reaction.Lancet,337, 1055 (1991).
Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer CA, Bloomfield CD. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia, a Cancer and Leukemia Group B Study (8762).Blood,80, 2983 (1992).
Kantarjian HM, Waiters RS, Keating MJ, Smith TL, O’Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, McCredie KB, Freireich EJ. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standardand high-risk acute lymphocytic leukemia.J Clin Oncol.,8, 994 (1990).
Linker CA, Levitt LJ, O’Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclic chemotherapy, a follow-up report.Blood,78, 2814 (1991).
Barrett AJ, Horowitz MM, Gale RP, Biggs JC, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB, Marmont AM, Masaoka T, Ramsay NKC, Rimm AA, Speck B, Zwaan FE, Bortin MM. Marrow transplantation for acute lymphoblastic leukemia, factors affecting relapse and survival.Blood,4, 862 (1989).
Barrett AJ, Joshi R, Kendra JR, Philips RH, Ashford R, Shaw PJ, Hugh-Jones K, Hobbs JR. Prediction and prevention of relapse of acute lymphoblastic leukemia after bone marrow transplantation.Br J Haematol.,64, 179 (1986).
Hoetzer D, Thiel E, Löffier H, Bodenstein H, Plaumann L, Büchner T, Urbanitz D, Koch P, Heimpel H, Engelhardt R, Müller U, Wendt F-C, Sodomann H, Rühl H, Herrmann F, Kaboth W, Dietzfelbinger H, Pralle H, Lunscken C, Hellriegel K-P, Spors S, Nowrousian RM, Fischer J, Ftille H, Mitrou PS, Pfreundschuh M, Emmerich CGB, Queisser w, Meyer P, Labedzki L, Essers U, König H, Mainzer K, Herrmann R, Messerer D, Zwingers T. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults.Blood,64, 38 (1984).
Hoelzer D. Prognostic factors in acute lymphoblastic leukemia.Leukemia,6 (suppl 4), 49 (1992).
Barnett MJ, Greaves MF, Amess JAL, Gregory WM, Rohatiner AZS, Dhaliwal HS, Slevin ML, Biruls R, Malpas JS, Lister TA. Treatment of acute lymphoblastic leukaemia in adults.Br J Haematol.,64, 455 (1986).
Drexler HG, Thiel E, Ludwig W-D. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia.Leukemia,5, 637 (1991).
Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner J, Griffin JD, Collins H, Nelson DA, Bloomfield CD. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia.N Engl J Med.,316, 1111 (1987).
Wingard JR, Piantadosi S, Santos GW, Saral R, Vriesendorp HM, Yeager AM, Burns WH, Ambinder RF, Braine HG, Elfenbein G, Jones RJ, Kaizer H, May WS, Rowtey SC, Sensenbrenner LL, Stuart RK, Tutschka PJ, Vogelsang GB, Wagner JE, Beschorner WE, Brookmeyer R, Farmer ER. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia.J Clin Oncol.,8, 820 (1990).
Doney K, Fisher LD, Appelbaum FR, Buckner CD, Storb R, Singer J, Fefer A, Anasetti C, Beatty P, Bensinger W, Clift R, Hansen J, Hill R, Loughran TP Jr, Martin P, Petersen FB, Sanders J, Sullivan KM, Stewart P, Weiden P, Witherspoon R, Thomas ED. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acutegraft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant,7, 453 (1991).
Buckner CD, Sanders JE, Hill R, Martin P, Doney K, Clift R, Appelbaum F, Petersen FB, Storb R, Bensinger W, Berenson R, Sullivan K, Thomas ED. Allogeneicversus autologous marrow transplantation for patients with acute lymphoblastic leukemia in first or second marrow remission, in Dicke KA, Spitzer G, Jagannath S, Evinger-Hodges MJ (ed):Autologous Bone Marrow Transplantation. Proceedings of the Fourth International Symposium, pp. 145–150, Houston, Texas, The University of Texas, M.D. Anderson Cancer Center (1989).
Doney K, Buckner CD, Kopecky KJ, Sanders JE, Appelbaum FR, Clift R, Sullivan K, Witherspoon R, Storb R, Thomas ED. Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission.Bone Marrow Transplant,2, 355 (1987).
Barrett AJ. Bone marrow transplantation for acute lymphoblastic leukemia, in Treleaven J, Barrett AJ (eds).Bone Marrow Transplantation in Practice, pp. 34–48, Churchill Livingstone, Edinburgh (1992).
Barrett AJ. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia.Leukemia,6 (suppl 2), 139 (1992).
Forman S J, O’Donnell MR, Nademanee AP, Snyder DS, Bierman PJ, Schmidt GM, Fahey L, Stein AS, Parker PM, Blume KG. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood,70, 587 (1987).
Barrett AJ, Horowitz MM, Ash RC, Atkinson K, Gale RP, Goldman JM, Henslee-Downey PJ, Herzig RH, Speck B, Zwaan FE, Bortin MM. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood,79, 3067 (1992).
Blume KG, Forman SJ, Snyder DS, Nademanee AP, O’Donnell MR, Fahey JL, Krance RA, Sniecinski IJ, Stock AD, Findley DO, Lipsett JA, Schmidt GM, Nathwani MB, Hill LR, Metter GE. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.Transplantation,43, 389 (1987).
Vernant JP, Marit G, Maraninchi D, Guyotat D, Kuentz M, Cordonnier C, Reiffers J. Allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia in first complete remission.J Clin Oncol.,6, 227 (1988).
Snyder DS, Chao NJ, Amylon MD, Taguchi J, Long GW, Negrin RS, Nademannee AP, O’Donnell MR, Schmidt GM, Stein AS, Parker PM, Smith EP, Stepan DE, Molina A, Lipsett JA, Hoppe RT, Niland JC, Dagis AC, Wong RM, Forman S J, Blume KG. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission.Blood,82, 2920 (1993).
Snyder DS, Findley DO, Forman SJ, Nademanee AP, O’Donnell MR, Schmidt GM, Bierman PJ, Fahey JL, Krance RA, Sniecinski IJ, Doelken G, Lipsett JA, Luk KH, Nathwani MB, Hill LR, Blume KG. Fractionated total body irradiation and high dose cyclophosphamide, a preparative regimen for bone marrow transplantation for patients with hematologic malignancies in first complete remission.Blut,57, 7 (1988).
Schmitz N, Gassmann W, Rister M, Johannson W, Suttorp M, Brix F, Holthuis JJM, Heit W, Hertenstein B, Schaub J, Loffier H. Fractionated total body irradiation and high-dose VP-16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.Blood,72, 1567 (1988).
Copelan EA, Biggs JC, Avalos BR, Szer J, Cunningham I, Klein JP, Atkinson K, Kapoor N, Klein JL, Downs K, Tutschka PJ. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.J Clin Oncol.,10, 237 (1992).
Blume KG, Kopecky KJ, Henslee-Downey JP, Forman S J, Stiff PJ, LeMaistre CF, Appelbaum FR. A prospective randomized comparison of total body irradiation-etoposideversus busulfan-yclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission, a Southwest Oncology Group study.Blood,81, 2187 (1993).
Champlin RE, Gale RP. Acute tymphobtastic leukemia, recent advances in biology and therapy.Blood,73, 2051 (1989).
Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation, results of the 1988–90 survey.Ann Intern Med,116, 505 (1992).
Report from the Working Party on Leukaemia, European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation for leukaemia in Europe.Lancet,2, 1379 (1988).
Herzig RH, Bortin MM, Barrett AJ, Blume KG, Gluckman E, Horowitz MM, Jacobsen S J, Marmont A, Masaoka T, Prentice HG, Ramsay NKC, Rimm AA, Ringdén O, Speck B, Zwaan FE, Gale RP. Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission.Lancet,1, 786 (1987).
Butturini A, Gale RP. Chemotherapyversus transplantation in acute leukaemia.Br J Haematol.,72, 1 (1989).
Butturini A, Bortin MM, Gale RP.Graft-versus-leukemia following bone marrow transplantation.Bone Marrow Transplant,2, 233 (1987).
Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomase ED.Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.N Engl J Med.,320, 828 (1989).
Thomas ED. Marrow transplantation for malignant disease.J Clin Oncol.,1, 517 (1983).
Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffman RG, Kay HEM, Kersey JH, Marmant A, Masaoka T, Rimm AA, van Rood JJ, Zwaan FE. Risk factors for acutegraft-versus-host disease.Br J Haematol.,67, 397 (1987).
Bross DS, Tutschka PJ, Farmer ET, Beschorner WE, Braine HG, Mellits ED, Bias WB, Santos GW. Predictive factors for acutegraft-versus-host disease in patients transplanted with HLA-identical bone marrow.Blood,63, 1265 (1984).
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringdén O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM.Graft-versus-leukemia reactions after bone marrow transplantation.Blood,75, 555 (1990).
Kersey JH, Weisdorf D, Nesbit ME, LeBien TW, Woods WH, McGlave PB, Kim T, Vallera DA, Goldman AI, Bostrom B, Hurd D, Ramsay NKC. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.N Engl J Med.,317, 461 (1987).
Weisdorf DJ, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A. Risk factors for acutegraft-versus-host disease in histocompatible donor bone marrow transplantation.Transplantation,51, 1197 (1991).
Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, enslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.N Engl J Med.,328, 593 (1993).
Ramsay NKC, Kersey JH. Indications for marrow transplantation in acute lymphoblastic leukemia.Blood,75, 815 (1990).
Gorin NC. Autologous bone marrow transplantation in hematological malignancies.Am J Clin Oncol.,14 (suppl), S5 (1991).
Lazarus HM, Rowe JM, Goldstone AH. Doesin vitro purging improve the outcome after autologous bone marrow transplantation?J Hematotherapy,2, 457 (1994).
Allieri MA, Lopez M, Douay L, Mary JY. Clonogenic leukemia progenitor cells in acute myelocytic leukemia are highly sensitive to cryopreservation, possible purging effect for autologous bone marrow transplantation.Bone Marrow Transplant,7, 101 (1991).
Labopin M, Gorin NC. Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe. a retrospective study.Leukemia,6 (suppl 4), 95 (1992).
Gorin NC, Aegerter P, Auvert B. Autologous bone marrow transplantation (ABMT) for acute leukaemia in remission, an analysis on 1322 cases.Bone Marrow Transplant,4 (suppl 2), 3 (1989).
Fière D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant J-P, Varet B, Broustet A, Cahn JY, Rigal-Huguet F, Witz F, Michaux J-L, Michallet M, Reiffers J. Adult acute lymphoblastic leukemia, a multicentric randomized trial testing bone marrow transplantation as postremission therapy.J Clin Oncol.,11, 1990 (1993).
Tura S. Long-term survivors in adult acute lymphoblastic leukemia.Bone Marrow Transplant,4 (suppl 1), 104 (1989).
Advisory Committee of the International Bone Marrow Transplant Registry. Report from the International Bone Marrow Transplant Registry.Bone Marrow Transplant,4, 221 (1989).
Carey PJ, Proctor S J, Taylor P, Hamilton PJ, and the Northern Regional Bone Marrow Transplant Group. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation.Blood,77, 1593 (1991).
Gilmore MJML, Hamon MD, Prentice HG. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukemia in first complete remission.Bone Marrow Transplant,8, 19 (1991).
Weisdorf DJ, Nesbit ME, Ramsay NKC, Wood WG, Goldman AI, Kim TH, Hurd DD, McGlave PB, Kersey JH. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission, prolonged survival associated with acutegraft-versus-host disease.J Clin Oncol.,5, 1348 (1987).
Jones R J, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB, Piantadosi S, Santos GW. Induction ofgraft-versus-host disease after autologous bone marrow transplantation.Lancet,1, 754 (1989).
Talbot DC, Powles RL, Sloane JP, Rose J, Treleaven J, Aboud H, Helenglass G, Parikh P, Smith C, Rowley M, Cavanagh J, Milliken S, Hewetson M, Norton J. Cyclosporine-inducedgraft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukemia.Bone Marrow Transplant,6, 17 (1990).
Yeager AM, Vogelsang GB, Jones R J, Farmer ER, Altamonte V, Hess AD, Santos GW. Induction of cutaneous graft-versus-dose disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia.Blood,79, 3031 (1992).
van Dongen JJ, Breit TM, Adriaansen HJ, Beishuizen A, Hookijkaas H. Detection of minimal residual in acute leukemia by immunological marker analysis and polymerase chain reaction.Leukemia,6 (suppl 1), 47 (1992).
Gehly GB, Bryant EM, Lee AM, Kidd PG, Thomas ED. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood,78, 458 (1991).
Biondi A, Yokota S, Hansen-Hagge TE, Rossi V, Giudici G, Maglia O, Basso G, Tell C, Masera G, Bartram CR. Minimal residual disease in childhood acute lymphoblastic leukemia, analysis of patients in continuous complete remission or with consecutive relapse.Leukemia,6, 282 (1992).
Uckun FM, Kersey JH, Haake R, Weisdorf D, Nesbit ME, Ramsay NKC. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia.N Engl J Med.,329, 1296 (1993),
Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.Lancet,341, 85 (1993).
Blaise D, Gaspard MH, Stoppa AM, Michel G, Gastaut JA, Lepeu G, Tubiana N, Blanc AP, Rossi JF, Novakovitch G, Mannoni P, Mawas C, Maraninchi D, Carcassonne Y. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.Bone Marrow Transplant,5, 7 (1990).
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, Buell D. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.N Engl J Med.,326, 845 (1992).
Rousey SR, Russler S, Gottleib M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation.Am J Med.,91, 484 (1991).
Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, Peters WP. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients.J Inf Dis.,165, 891 (1992).
Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation.N Engl J Med.,314, 1006 (1986).
Elfenbein G, Krischer K, Graham-Pole J, Hong R, Jansen J, Lazarus H. Intravenous immunoglobulins for cytomegalovirus pneumonia. In. Imbach P, ed.Immunotherapy with Intravenous Immunoglobulin, pp. 219–229, London, Academic Press Ltd. (1991).
Reed EC, Bowden RN, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobin in patients bone marrow transplants.Ann Intern Med.,109, 783 (1988).
Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J, Stover D, White DA, Fels A, Polsky B, Castro-Malaspina H, Peppard JR, Bartus P, Hammerling U, O’Reilly RJ. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with a combination of ganciclovir and high-dose intravenous immune globulin.Ann Intern Med.,109, 777 (1988).
Reed E, Bowden R, Dandliker P, Lilleby PS, Meyers JD. Treatment of cytomegalovirus pneumonia in marrow transplant patients with ganciclovir and intravenous cytomegalovirus immunoglobulin, in, Dicke KA, Spitzer G, Jagannath S, (eds.),Autologous Bone Marrow Transplantation.Proceedings of the Fourth International Symposium, pp. 743–746, Houston, University of Texas, MD Andersen Hospital (1989).
Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman S J, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.N Engl J Med.,324, 1005 (1991).
Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, De Armond B, Meyers JD. Early treatment with ganciclovir to prevent cytomegalovims disease after allogeneic bone marrow transplantation.N Engl J Med.,325, 1601 (1991).
Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner CD, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.N Engl J Med.,324, 1773 (1991).
Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemeister FB, Souza LM. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin’s disease.J Clin Oncol.,7, 1791 (1989).
Gulati CG, Bennett CL. Granulocyte-macrophage colony-stimulating-factor (GM-CSF) as adjunct therapy in relapsed Hodgkin’s disease.Ann Intern Med 116, 177 (1992),
Mertelsmann R, Herrmann F, Hecht T, Schulz G. Hematopoietic growth factors in bone marrow transplantation.Bone Marrow Transplant,6, 73 (1990).
Powles R, Smith C, Milan S, Treleaven J, Millar J, McElwain T, Gordon-Smith E, Millikens S, Tiley C. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia, double-blind, placebo-controlled trial.Lancet,336, 1417 (1990).
Masaoka T, Takaku F, Kato S, Moriyama Y, Kodera Y, Kanamaru A, Shimosaka A, Shibata H, Nakamura H. Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation.Exp Hematol.,17, 1047 (1989).
Blazar BR, Kersey JH, McGlave PB, Vallera DA, Lasky LC, Haake RJ, Bostrom B, Weisdorf DR, Epstein C, Ramsay NKC.In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts.Blood,73, 849 (1989).
Lazarus HM, Andersen J, Chen MG, Variakojis D, Mansour EG, Oette D, Arce CA, Oken MM, Gerson SL. Recombinant granulocyte- macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin’s lymphoma, blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial.Blood,78, 830 (1991).
Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O’Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acutegraft-versus-host disease.N Engl J Med.,329, 1225 (1993).
Nemunaitis J, Buckner CD, Appelbaum FR, Higano CS, Mori M, Bianco J, Epstein C, Lipani J, Hansen J, Storb R, Thomas ED, Singer J. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation.Blood,77, 2065 (1991).
Bostrom B, Weisdorf D J, Kim T, Kersey JH, Ramsay NKC. Bone marrow transplantation for advanced acute leukemia, a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.Bone Marrow Transplant,5, 83 (1990).
Horowitz MM, Messerer D, Hoetzer D, Gale RP, Neiss A, Atkinson K, Barrett AL Btichner T, Freund M, Heil G, Hiddemann W, Kolb H-J, Löffier H, Marmont AM, Maschmeyer G, Rimm AA, Rozman C, Sobocinski KA, Speck B, Thiel E, Weisdorf DJ, Zwaan FE, Bortin MM. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission.Ann Intern Med.,115, 13 (1991).
Berman E, Little C, Gee T, O’Reilly R, Clarkson B. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation.N Engl J Med.,326, 156 (1992).
Dicke KA, Hoelzer DF, Gorin NC, Lowenberg B, Gale RP. The role of bone marrow transplantation in adult acute lymphocytic leukemia.Ann Oncol.,4 (suppl 1), S81 (1993).
Linker CA, Levitt LJ, O’Donnell MR, Ries CA, Link MP, Forman S J, Farbstein MJ. Improved results of treatment of adult acute lymphoblastic leukemia.Blood,69, 1242 (1987).
Jacobs AD, Gale RP. Recent advances in the biology and treatment of acute lymphoblastic leukemia.N Engl J Med.,311, 1219 (1984).
Chao NJ, Blume KG. Bone marrow transplantation, what is the question?Ann Intern Med.,113, 340 (1990).
Coiffier B, Philip T, Burnett AK, Symann ML. Consensus Conference on Intensive Chemotherapy plus Hematopoietic Stem-Cell Transplantation in Malignancies. Lyon, France, June 4–6, 1993.J Clin Oncol.,12, 226 (1994).
Eastern Cooperative Oncology Group and Medical Research Council of United Kingdom. E2993 and MRC UK XII. Phase III randomized trial of autologous and allogeneic bone marrow transplantationversus intensive conventional chemotherapy in acute lymphoblastic leukemia in first remission.
Vemant JP, Sutton L, Kuentz M, Maraninchi D, Gluckman E, Fibre D, LeBlond V, Cahn JY, Witz F, Cordonnier C. Allogeneic bone marrow transplantation in 184 adults with acute lymphoid leukemia in first complete remission (abstract).Proc Am Soc Clin Oncol.,9, 12, (1990)
Author information
Authors and Affiliations
Additional information
This article was presented, in part, at the Eleventh Annual Advances in Cancer Treatment Research Symposium, Albert Einstein College of Medicine, March 23–25, 1994, New York, New York.
Rights and permissions
About this article
Cite this article
Lazarus, H.M., Rowe, J.M. Bone marrow transplantation for acute lymphoblastic leukemia(all). Med Oncol 11, 75–88 (1994). https://doi.org/10.1007/BF02988834
Issue Date:
DOI: https://doi.org/10.1007/BF02988834